New award for ublituximab-xiiy 150MG/6ML injection (anti-CD20 antibodies with TG therapeutics. Period of performance june 17, 2024 - june 16, 2025 with four one-year options.

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79724D0024
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 79% complete
IDV ceiling
$186,776,520.00
Award type
Single award
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 4 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

The Department of Veterans Affairs National Acquisition Center awarded an indefinite-delivery contract to TG Therapeutics Inc. for ublituximab-XIIY 150mg/6ml injection (anti-CD20 antibodies) with a ceiling of $186.776 million on June 17, 2024. This is a single-award contract with no set-aside.

The contract covers nationwide distribution through the VA Pharmaceutical Prime Vendor program. TG Therapeutics' product becomes the preferred anti-CD20 antibody listed on the VA National Formulary for treatment of specified conditions in veterans, required for new patient starts unless clinically contraindicated.

The solicitation, posted January 25, 2024, requested pricing for three anti-CD20 antibodies—ocrelizumab, ublituximab-XIIY, and ofatumumab. Offerors were required to submit five-year pricing for one line item to be considered; TG Therapeutics' submission for ublituximab-XIIY prevailed. The contract falls under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6515 (Medical Supplies).

Period of performance runs from June 17, 2024 through June 16, 2025, with four one-year options exercisable through June 16, 2027. The contract incorporates Section 5 of Executive Order 14398 and FAR 52.222-90, addressing discrimination and diversity requirements.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00007 · This modification incorporates section 5 of EO 14398, clause 52.222-90, addressing DEI discrimination $0
Exercise an Option P00006 · This modification is issued to exercise option year two for anti-CD20 antibodies with TG therapeutics. $0
Other Administrative Action P00005 · This modification incorporates 2026 public law pricing updates into the contract. There are no changes to the awarded contract pricing. $0
Exercise an Option P00004 · This modification is issued to exercise option year one for anti-CD20 antibodies with TG therapeutics. $0
Other Administrative Action P00003 · This modification incorporates 2025 public law pricing updates into the contract. There are no changes to the awarded contract pricing. $0
Vendor Address Change P00002 · This modification is issued to incorporate a change of address into VA national contract 36E79724D0024. $0
Supplemental Agreement for work within scope P00001 · This modification is issued to update the terms of the CRF payment remittal and submission of quarterly sales reports. $0
Original award $0

Quick answers

Who was awarded contract 36E79724D0024?

36E79724D0024 was awarded to TG Therapeutics Inc. by National Acquisition Center (Headquarters) on June 17, 2024.

How much is contract 36E79724D0024 worth?

36E79724D0024's own ceiling is $186,776,520.

Who can order from contract 36E79724D0024?

36E79724D0024 is a single award indefinite delivery contract.

Was contract 36E79724D0024 competed?

The extent of competition for 36E79724D0024 was full and open competition. The government received 4 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login